BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 28355969)

  • 1. Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.
    Christ TN; Stock W; Knoebel RW
    J Oncol Pharm Pract; 2018 Jun; 24(4):299-308. PubMed ID: 28355969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia.
    Aldoss I; Douer D; Behrendt CE; Chaudhary P; Mohrbacher A; Vrona J; Pullarkat V
    Eur J Haematol; 2016 Apr; 96(4):375-80. PubMed ID: 26095294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicity Profile of PEG-Asparaginase in Adult Patients With Acute Lymphoblastic Leukemia in Brazil: A Multicenter Cross-Sectional Study.
    Silva WFD; Massaut IHB; Bendlin RM; Rosa LI; Velloso EDRP; Rego EM; Rocha V
    Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):e523-e528. PubMed ID: 32389674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
    Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
    Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens.
    Denton CC; Rawlins YA; Oberley MJ; Bhojwani D; Orgel E
    Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29218844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study.
    Abshire TC; Pollock BH; Billett AL; Bradley P; Buchanan GR
    Blood; 2000 Sep; 96(5):1709-15. PubMed ID: 10961868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute pancreatitis in children with acute lymphoblastic leukemia after chemotherapy.
    Treepongkaruna S; Thongpak N; Pakakasama S; Pienvichit P; Sirachainan N; Hongeng S
    J Pediatr Hematol Oncol; 2009 Nov; 31(11):812-5. PubMed ID: 19801948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses.
    Burke PW; Aldoss I; Lunning MA; Devlin SM; Tallman MS; Pullarkat V; Mohrbacher AM; Douer D
    Leuk Res; 2018 Mar; 66():49-56. PubMed ID: 29407583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia].
    Cooperation Group of Phase II Clinical Trial of PEG-Asp
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):29-33. PubMed ID: 18512312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management.
    Bade NA; Lu C; Patzke CL; Baer MR; Duong VH; Law JY; Lee ST; Sausville EA; Zimrin AB; Duffy AP; Lawson J; Emadi A
    J Oncol Pharm Pract; 2020 Jan; 26(1):74-92. PubMed ID: 30917738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study.
    Albertsen BK; Grell K; Abrahamsson J; Lund B; Vettenranta K; Jónsson ÓG; Frandsen TL; Wolthers BO; Heyman M; Schmiegelow K
    J Clin Oncol; 2019 Jul; 37(19):1638-1646. PubMed ID: 30978155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia.
    Larson RA; Fretzin MH; Dodge RK; Schiffer CA
    Leukemia; 1998 May; 12(5):660-5. PubMed ID: 9593262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. National Italian Delphi panel consensus: which measures are indicated to minimize pegylated-asparaginase associated toxicity during treatment of adult acute lymphoblastic leukemia?
    Lussana F; Minetto P; Ferrara F; Chiaretti S; Specchia G; Bassan R
    BMC Cancer; 2020 Oct; 20(1):956. PubMed ID: 33008391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fulminant hepatitis possibly caused by L-asparaginase during induction chemotherapy in a patient with acute lymphoblastic leukemia].
    Tsutsui M; Koike M; Komatsu N
    Rinsho Ketsueki; 2012 May; 53(5):531-4. PubMed ID: 22728556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful use of octreotide as a chemoprotectant for prevention of PEG-asparaginase-induced pancreatitis.
    Buie LW; Moore J; van Deventer H
    Pharmacotherapy; 2014 Aug; 34(8):e149-51. PubMed ID: 25112526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypertriglyceridemia during asparaginase treatment in children with acute lymphoblastic leukemia correlates with antithrombin activity in adolescents.
    Persson L; Harila-Saari A; Hed Myrberg I; Heyman M; Nilsson A; Ranta S
    Pediatr Blood Cancer; 2017 Oct; 64(10):. PubMed ID: 28440015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia.
    Schulte R; Hinson A; Huynh V; Breese EH; Pierro J; Rotz S; Mixon BA; McNeer JL; Burke MJ; Orgel E
    Cancer Med; 2021 Nov; 10(21):7551-7560. PubMed ID: 34528411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol.
    Raja RA; Schmiegelow K; Albertsen BK; Prunsild K; Zeller B; Vaitkeviciene G; Abrahamsson J; Heyman M; Taskinen M; Harila-Saari A; Kanerva J; Frandsen TL;
    Br J Haematol; 2014 Apr; 165(1):126-33. PubMed ID: 24428625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia.
    Ettinger LJ; Kurtzberg J; Voûte PA; Jürgens H; Halpern SL
    Cancer; 1995 Mar; 75(5):1176-81. PubMed ID: 7850718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety profile of a single pegylated asparaginase (PEG-ASP) dose in remission induction for acute lymphoblastic leukemia (ALL).
    Helbig G; Armatys A; Boral K; Kopinska AJ; Wozniczka K; Dworaczek M; Chromik K; Koclega A; Panz-Klapuch M; Wysocka M; Janikowska A
    Neoplasma; 2018 Nov; 65(6):993-997. PubMed ID: 29940768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.